Ose Pharma International S.A.
Records under this name other than patents Ose Pharma International S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Ose Pharma International S.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,007,810 | HLA-A2 Tumor Associated Antigen Peptides and Compositions Term ended Term ended Apr 16, 2024 · High confidence | Term ended | Term ended Apr 16, 2024 | High confidence |
| US 9,394,350 | HLA-A2 Tumor Associated Antigen Peptides and Compositions Term ended Term ended Apr 16, 2024 · High confidence | Term ended | Term ended Apr 16, 2024 | High confidence |
| US 9,913,884 | HLA-A2 Tumor Associated Antigen Peptides and Compositions Term ended Term ended Apr 16, 2024 · High confidence | Term ended | Term ended Apr 16, 2024 | High confidence |
| US 7,252,829 | HLA binding peptides and their uses Term ended Ended no later than Jun 17, 2018 · USPTO record | Term ended | Ended no later than Jun 17, 2018 | USPTO record |
| US 6,602,510 | HLA class I A2 tumor associated antigen peptides and vaccine compositions Lapsed on the fee record Ended Aug 5, 2011 · USPTO record | Lapsed on the fee record | Ended Aug 5, 2011 | USPTO record |